Literature DB >> 15717013

The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Julie Leegwater-Kim1, Jang-Ho J Cha.   

Abstract

Despite a relatively small number of affected patients, Huntington's disease (HD) has been a historically important disease, embodying many of the major themes in modern neuroscience, including molecular genetics, selective neuronal vulnerability, excitotoxicity, mitochondrial dysfunction, apoptosis, and transcriptional dysregulation. The discovery of the HD gene in 1993 opened the door to the mechanisms of HD pathogenesis. Multiple pathologic mechanisms have been discovered, each one serving as a potential therapeutic target. HD thus continues to serve as a paradigmatic disorder, with basic bench research generating clinically relevant insights and stimulating the development of therapeutic human trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15717013      PMCID: PMC534918          DOI: 10.1602/neurorx.1.1.128

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  153 in total

1.  Riluzole in Huntington's disease (HD): an open label study with one year follow up.

Authors:  K Seppi; J Mueller; T Bodner; E Brandauer; T Benke; H Weirich-Schwaiger; W Poewe; G K Wenning
Journal:  J Neurol       Date:  2001-10       Impact factor: 4.849

2.  Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

Authors:  P Guidetti; V Charles; E Y Chen; P H Reddy; J H Kordower; W O Whetsell; R Schwarcz; D A Tagle
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

3.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

4.  A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.

Authors: 
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

5.  Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

Authors:  I Mizuta; M Ohta; K Ohta; M Nishimura; E Mizuta; S Kuno
Journal:  Neurosci Lett       Date:  2001-09-14       Impact factor: 3.046

6.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Mutant huntingtin enhances excitotoxic cell death.

Authors:  M M Zeron; N Chen; A Moshaver; A T Lee; C L Wellington; M R Hayden; L A Raymond
Journal:  Mol Cell Neurosci       Date:  2001-01       Impact factor: 4.314

8.  Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing.

Authors:  D Rigamonti; S Sipione; D Goffredo; C Zuccato; E Fossale; E Cattaneo
Journal:  J Biol Chem       Date:  2001-03-05       Impact factor: 5.157

9.  Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.

Authors:  P Calabresi; P Gubellini; B Picconi; D Centonze; A Pisani; P Bonsi; P Greengard; R A Hipskind; E Borrelli; G Bernardi
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

View more
  18 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 2.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

3.  Sertoli Cells Avert Neuroinflammation-Induced Cell Death and Improve Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.

Authors:  Houssein Ahmadi; Mahdi Eskandarian Boroujeni; Yousef Sadeghi; Mohammad Amin Abdollahifar; Fariba Khodagholi; Gholam Houssein Meftahi; Mohammadmehdi Hadipour; Amir-Hossein Bayat; Fatemeh Shaerzadeh; Abbas Aliaghaei
Journal:  J Mol Neurosci       Date:  2018-04-21       Impact factor: 3.444

4.  Progressive reparative gliosis in aged hosts and interferences with neural grafts in an animal model of Huntington's disease.

Authors:  Yvona Mazurová; Ivan Látr; Jan Osterreicher; Ivana Guncová
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

5.  Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease.

Authors:  M Mühlau; A Weindl; A M Wohlschläger; C Gaser; M Städtler; M Valet; C Zimmer; J Kassubek; A Peinemann
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

6.  Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.

Authors:  Sumit Jamwal; Shamsher Singh; Navneet Kaur; Puneet Kumar
Journal:  Neurotox Res       Date:  2015-06-16       Impact factor: 3.911

7.  Cognitive follow up of a small cohort of Huntington's disease patients over a 5 year period.

Authors:  Sarah L Mason; Ruwani Wijeyekoon; Rachel Swain; Aileen K Ho; Emma L Smith; Barbara Sahakian; Roger A Barker
Journal:  PLoS Curr       Date:  2010-09-02

8.  Bridging the Metabolic Parallels Between Neurological Diseases and Cancer.

Authors:  Shenghao Guo; Yanni Gu; Jiayin Qu; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  A pilot assessment of parental practices and attitudes regarding risk disclosure and clinical research involving children in Huntington disease families.

Authors:  Leon S Dure; Kimberly Quaid; T Mark Beasley
Journal:  Genet Med       Date:  2008-11       Impact factor: 8.822

10.  Effects of Panax ginseng in Neurodegenerative Diseases.

Authors:  Ik-Hyun Cho
Journal:  J Ginseng Res       Date:  2012-10       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.